Radium 223 Dichloride in Combination with Androgen Deprivation Therapy and Stereotactic Body Radiation Therapy for Patients with Stage IV Oligometastatic Castration Sensitive Prostate Cancer: Clinical Trial in Progress

For patients with oligometastatic prostate cancer there is an emerging data suggesting benefit of localized treatment of metastases with stereotactic body radiation therapy (SBRT) as an addition to systemic therapy. Bone metastases are the most common site of oligometastatic disease thus targeting the bone niche may help prevent spread of oligometastatic and micrometastatic disease. Radium 223 dichloride acts as a calcium mimetic targeting active areas of bone turnover observed in osteoblastic lesions.

Source: International Journal of Radiation Oncology * Biology * Physics - July 19, 2019 Category: Radiology Authors: S.V. Dandapani, T.B. Dorff, M. Kortylewski, P. Frankel, P. Twardowski Tags: Publish Only Source Type: research